Codex DNA Shares Move Higher On Licensing, Supply Deal With TriLink For mRNA Capping Tech

Codex DNA Inc DNAY has announced a licensing and supply agreement with TriLink Biotechnologies, part of Maravai LifeSciences Holdings Inc MRVI for CleanCap technology.
Codex DNA will integrate the mRNA capping technology into its suite of automated mRNA synthesis kits for the BioXp system and within the company's BioFoundry Services offering.
Together, the technologies are expected to increase productivity and yields for mRNA synthesis workflows.
Customers will now have the option to generate up to 16 biologically active mRNA constructs at a yield of at least 10 micrograms each from fully de novo synthesized and error-corrected genes in a single automated run.
Price Action: DNAY shares are up 10.4% at $17.50, while MRVI shares are down 2.37% at $39.38 during the market session on the last check Wednesday.

Momentum2.91

Growth-

Quality-

Value33.14

Short

Medium

Long